Resources
Newsroom
Press Releases
Company Publications
FAQs
Frequently Asked Questions
Scientific Papers
Related Scientific Publications
Press Releases
Amira Therapeutics Receives Orphan Drug Designation for AMI463 in Soft Tissue Sarcoma in the United States
Amira therapeutics has received orphan drug designation (ODD) for its compound AMI463 by the FDA. The compound had previously received the designation of rare pediatric disease, also by the FDA, and ODD itself by the EMA. Amira is associated with the Fundació Mutua...
Scientific Papers
Cell biology of protein–lipid conjugation
By Jun-ichi Sakamaki and Noboru Mizushima Cell Structure and Function, 2023, Volume 48, Issue 1, Pages 99-112, Released on J-STAGE May 11, 2023, Advance online publication April 06, 2023, Online ISSN 1347-3700, Print ISSN 0386-7196, https://doi.org/10.1247/csf.23016...
Targeting the Hedgehog Pathway in Rhabdomyosarcoma
by Patricia Zarzosa, Lia Garcia-Gilabert, Raquel Hladun, Gabriela Guillén, Gabriel Gallo-Oller, Guillem Pons, Julia Sansa-Girona, Miguel F. Segura, Josep Sánchez de Toledo, Lucas Moreno, Soledad Gallego, and Josep Roma Cancers 2023, 15(3),...
RCAN1-mediated calcineurin inhibition as a target for cancer therapy
By Mengyi Lao, Xiaozhen Zhang, Hanshen Yang, Xueli Bai, and Tingbo Liang Molecular Medicine volume 28, Article number: 69 (2022) DOI: https://doi.org/10.1186/s10020-022-00492-7 Abstract Cancer is the leading cause of mortality worldwide. Regulator of calcineurin...
F.A.Q.s
Where is Amira Therapeutics Incorporated?
Amira Therapeutics is a Spanish limited liability company, incorporated on April 23, 2021, in Barcelona, Spain, with VAT number B05407515.
Who is the current owner of Amira Therapeutics?
Amira Therapeutics SL is a company majority-owned by Acondicionamiento Tarrasense, a private technology center founded in 1906 and operating under the Leitat commercial brand. Since 2023, the MGC foundation has been part of the company, owning a minority stake.
How many employees does Amira Therapeutics currently have?
Amira Therapeutics currently has one employee.
Does Amira Therapeutics have any relationship with Amira Pharmaceuticals?
No, Amira Therapeutics and Amira Pharmaceuticals have no relationship. Amira Pharmaceuticals was acquired by Bristol Myers Squibb for $325 million in July 2011, ceasing operations. Until then, Amira Pharmaceuticals was a company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases, while Amira Therapeutics is focused on developing treatments for pediatric cancer.